Small molecules targeting BRCA1-deficient cancer cells
BRCA1 mutation-carriers frequently develop triple-negative breast cancers that are resistant to cancer therapies. We used our established luciferase-expressing BRCA1-deficient human mammary epithelial-derived cell line series with stable shRNA-mediated BRCA1-knockdown, H-RasG12V-mediated transformation, and TP53-deficiency (PMID: 20038817) to perform a high-throughput-screen using the National…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.